ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA episode artwork

EPISODE · Jul 4, 2025 · 18 MIN

ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA

from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies.Episode Highlights:• KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma• AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer• ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now• NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategiesYouTube: https://youtu.be/Rt8HQpdyVY0Follow us on social media:•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers•⁠ Website: https://oncbrothers.com/Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies.Episode Highlights:• KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma• AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer• ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now• NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategiesYouTube: https://youtu.be/Rt8HQpdyVY0Follow us on social media:•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers•⁠ Website: https://oncbrothers.com/Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!

NOW PLAYING

ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA

0:00 18:16

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Destiny Architecture® Meditations Heather Larson Bring your mediation practice into the Valueverse. Solving for Change MOBIA Technology Innovations Solving for Change welcomes business and technology leaders to share stories of bold business transformation within complex organizations. In an era when technology and markets are changing around businesses, the key to staying competitive is to evolve in response to those changes.  MOBIA’s Mike Reeves and Marc LeBlanc investigate business transformation, deconstructing the challenges, ambitions, and market disruptions that drive companies to embark on transformation journeys, and exploring their unique approaches to achieving meaningful outcomes.  What sparks leaders to pursue business transformation? How do they overcome the challenges along the way? What are the keys to creating enduring change?  Through in-depth conversations with business and technology leaders, Mike and Marc answer these questions and explore how businesses evolve by pulling four key transformation levers: people, process, technology, and culture. The Lee Olsen Show Lee Olsen CJF I want to help you improve all areas of your life by 3 types of podcasts!👉Blood, Sweat & Blessings-Interviews of normal people that have achieved BIG things!👉Series!!! For Love of the Horse- Brad Jackman DVM & Lee Olsen CJF, how to help your horse!👉Business Tips- Proven Life Changing Business Strategies with Lee Olsen Darknet Discussions Darknet Discussions Welcome to "Darknet Discussions," the podcast that gets into the shadows of the internet to bring you the most intriguing, enlightening, and sometimes unsettling stories from the dark web. Hosted by seasoned darknet aficionados, each episode of "Darknet Discussions" explores the intricate dynamics of darknet markets, cybersecurity threats, and the digital underworld. Join us as we interview experts, discuss the latest trends in cybercrime, and shed light on the technologies that operate beneath the surface of everyday internet use. Also, we occasionally go off on a tangent about something completely unrelated.

Frequently Asked Questions

How long is this episode of Oncology Brothers: Practice-Changing Cancer Discussions?

This episode is 18 minutes long.

When was this Oncology Brothers: Practice-Changing Cancer Discussions episode published?

This episode was published on July 4, 2025.

What is this episode about?

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual...

Can I download this Oncology Brothers: Practice-Changing Cancer Discussions episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!